Intraperitoneal PX with nab-paclitaxel for mucinous adenocarcinoma with peritoneal spread
Part of Cancer clinical trials.
This trial tests a new treatment for a type of cancer that has spread to the lining of the belly. The treatment is given directly into the belly along with a standard chemotherapy drug to try to slow the cancer and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be a mucinous adenocarcinoma that has spread to the lining of your belly (peritoneum) — this must be confirmed by a biopsy or surgery.
- You must be well enough to care for yourself (ECOG performance status 0-2), meaning you are up and about at least half of the day.
- Your liver, kidneys, and blood counts must be within acceptable ranges, as checked by blood tests within 7 days before you join.
- You must not have had chemotherapy or radiation in the last 4 weeks (or 6 weeks for certain stronger drugs).
- You must not have severe abdominal infections, bowel blockages, or significant nerve damage in your hands or feet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This trial tests a new way to give chemotherapy directly into the belly as a fine mist (called PIPAC) for people whose cancer has spread there. The goal is to see if it’s safe and helps shrink or control the cancer.
This trial tests a chemotherapy drug (paclitaxel) given directly into the belly for people whose appendix cancer has spread inside the belly and cannot be surgically removed. The goal is to see if this approach is safe and helps shrink tumors.
This trial tests a combination of treatments for stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink or control the cancer, potentially making surgery possible.
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
Hear when a new Peritoneal (Metastatic) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.